Hussein Assi, MD, MS
Assistant Professor
Boston University Chobanian & Avedisian School of Medicine
Hematology & Medical Oncology

MD, Amer Univ of Beirut
MS, University of Oklahoma
BS, Amer Univ of Beirut
favorite icon LinkedIn

Dr. Assi is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the section of Hematology/Oncology at Boston Medical Center (BMC). He graduated from medical school at the American University of Beirut in Lebanon and completed his residency in Internal Medicine at Albany Medical Center in Albany, NY. He further completed his training in Hematology/Oncology at University of Oklahoma Health Sciences Center, while also receiving a Master's degree in Clinical and Translational Sciences. His work is focuses on gastrointestinal malignancies, with special focus on neuroendocrine tumors (NETs). His aim is to establish himself as an independent clinical investigator, with a focus on delivering novel therapeutics in NETs. His current research focuses on studying prognostic biomarkers in pancreatic NETs.

Diversity, Equity, Inclusion and Accessibility

I am deeply committed to Boston Medical Center's mission of "exceptional care without exception". For me, this means providing care and the utmost empathy to all patients, regardless of race, ethnicity, religious views, sexual orientation, socioeconomic status, or spoken language. Recognizing that we all have our implicit biases which we can always improve on, I aim to continue to be mindful during my interactions with my surrounding, including other faculty, staff, and patients.

09/27/2023 - 09/26/2026 (PI)
RayzeBio, Inc.

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects with Carcinoid Syndrome
09/21/2022 - 09/20/2025 (PI)
Crinetics Pharmaceuticals, Inc


Yr Title Project-Sub Proj Pubs

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Hackeng WM, Assi HA, Westerbeke FHM, Brosens LAA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surg Pathol Clin. 2022 Sep; 15(3):541-554.View Related Profiles. PMID: 36049835; DOI: 10.1016/j.path.2022.05.007;
  2. Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021 07 01; 50(6):890-894. PMID: 34398071
  3. Assi HA, Shikdar S, Alhyari L, Aljumaily R. Long-Term Survival With Nanoliposomal Irinotecan in Pancreatic Cancer. Pancreas. 2020 10; 49(9):e95-e96. PMID: 33003100
  4. Assi HA, Asch AS, Machiorlatti M, Vesely SK, Ibrahimi S. Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy. Future Sci OA. 2020 Jun 25; 6(7):FSO581. PMID: 32802390; PMCID: PMC7421541; DOI: 10.2144/fsoa-2020-0021;
  5. Assi HA, Mukherjee S, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. Anticancer Res. 2020 Feb; 40(2):847-855. PMID: 32014928
  6. Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. J Urol. 2020 07; 204(1):63-70. PMID: 31971495; PMCID: PMC7289665; DOI: 10.1097/JU.0000000000000761;
  7. Assi HA, Padda SK. Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. Cancer Treat Res Commun. 2020 Jan 16; 23:100167. PMID: 32007735
  8. Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. Cancer. 2020 03 15; 126(6):1208-1216. PMID: 31829450; PMCID: PMC7050422; DOI: 10.1002/cncr.32645;
  9. Assi HA, Mukherjee S, Kunz PL, Machiorlatti M, Vesely S, Pareek V, Hatoum H. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database. Oncologist. 2020 02; 25(2):e276-e283. PMID: 32043766; PMCID: PMC7011621; DOI: 10.1634/theoncologist.2019-0466;
  10. Assi HA, Patel R, Mehdi S. Neuroendocrine carcinoma of the larynx with metastasis to the eyelid. J Community Support Oncol. 2015 Oct; 13(10):378-80. PMID: 26862914
Showing 10 of 18 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 18 publications over 8 distinct years, with a maximum of 5 publications in 2020


2020 University of Oklahoma Health Sciences Center: Outstanding Fellow in Hematology and Oncology Award
2020 University of Oklahoma Graduate College: Alpha Epsilon Lambda (AEL) National Honor Society
2019 University of Oklahoma College of Medicine: Alpha Omega Alpha (AOA) Honor Medical Society
2018 American Society of Hematology: Abstract Achievement Award
Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map

Assi's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department